Novavax to Participate in Upcoming Conferences
26 November 2020 - 8:15AM
Novavax Inc. (Nasdaq: NVAX), a late-stage biotechnology company
developing next-generation vaccines for serious infectious
diseases, today announced that it will participate in two upcoming
investor conferences. Novavax’ COVID-19 vaccine candidate,
NVX-CoV2373, will be a topic of discussion in each conference.
Piper Sandler
32nd Annual Virtual
Healthcare Conference |
PanelDate: |
Tuesday, December 1, 2020 |
Time: |
10:00 a.m. Eastern Time (ET) |
Panel title: |
The Road Ahead for COVID-19 Vaccines: What We Know and Questions
Still to Be Answered into 2021 |
Moderators: |
Edward A. Tenthoff and Yasmeen Rahimi, Ph.D. |
NVAX Panelist: |
Gregory M. Glenn, M.D., President of Research and Development,
NovavaxAdditional panelists: Moderna, Inc., Arcturus Therapeutics
Holdings, Inc. and Altimmune, Inc. This event is open to Piper
Sandler clients |
|
|
Conference |
|
Event:Participants: |
Fireside chat Stanley C. Erck, President and Chief Executive
Officer, and Dr. Glenn |
Webcast: |
A replay of the recorded fireside session is available through the
events page of the Company’s website at ir.novavax.com for 90
days. |
|
|
Event:Date: |
Investor meetings Wednesday, December 2, 2020 |
Evercore ISI
3rd Annual HealthCONx
Conference |
Date: |
Thursday, December 3, 2020 |
Time: |
2:15 p.m. Eastern Time (ET) |
Participation: |
Fireside chat and investor meetings |
Live webcast: |
www.novavax.com, “Investors”/ “Events” |
|
|
About NVX-CoV2373
NVX-CoV2373 is a vaccine candidate engineered
from the genetic sequence of SARS-CoV-2, the virus that causes
COVID-19 disease. NVX-CoV2373 was created using Novavax’
recombinant nanoparticle technology to generate antigen derived
from the coronavirus spike (S) protein and contains Novavax’
patented saponin-based Matrix-M™ adjuvant to enhance the immune
response and stimulate high levels of neutralizing antibodies.
NVX-CoV2373 contains purified protein antigen and cannot replicate,
nor can it cause COVID-19. In preclinical trials, NVX-CoV2373
demonstrated induction of antibodies that block binding of spike
protein to receptors targeted by the virus, a critical aspect for
effective vaccine protection. In the Phase 1 portion of its Phase
1/2 clinical trial, NVX-CoV2373 was generally well-tolerated and
elicited robust antibody responses numerically superior to that
seen in human convalescent sera. NVX-CoV2373 is also being
evaluated in a Phase 3 trial in the U.K. and two ongoing Phase 2
studies that began in August; a Phase 2b trial in South Africa, and
a Phase 1/2 continuation in the U.S. and Australia. Novavax has
secured $2 billion in funding for its global coronavirus vaccine
program, including up to $399 million in funding from the Coalition
for Epidemic Preparedness Innovations (CEPI) and almost $1.7
billion from the U.S.
government.
About Novavax
Novavax, Inc. (Nasdaq: NVAX) is a late-stage
biotechnology company that promotes improved health globally
through the discovery, development, and commercialization of
innovative vaccines to prevent serious infectious diseases.
Novavax is currently conducting multiple clinical trials for
NVX-CoV2373, its vaccine candidate against the virus that causes
COVID-19, including a pivotal Phase 3 clinical trial in the United
Kingdom to evaluate the efficacy, safety and immunogenicity in
individuals aged 18-84 years of age. NanoFlu™, its quadrivalent
influenza nanoparticle vaccine, met all primary objectives in its
pivotal Phase 3 clinical trial in older adults. Both candidate
vaccines incorporate Novavax’ proprietary saponin-based Matrix-M™
adjuvant to enhance the immune response and stimulate high levels
of neutralizing antibodies. Novavax is a leading innovator of
recombinant vaccines; its proprietary recombinant technology
platform combines the power and speed of genetic engineering to
efficiently produce highly immunogenic nanoparticles in order to
address urgent global health needs.
For more information, visit www.novavax.com and
connect with us on Twitter and LinkedIn.
Contacts:
InvestorsErika Trahanir@novavax.com240-268-2022
Media Brandzone/KOGS CommunicationEdna Kaplan kaplan@kogspr.com
617-974-8659
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Apr 2023 to Apr 2024